Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA — Rio de Janeiro

Public research footprint of Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Most-studied conditions

Carcinoma, Non-Small-Cell Lung · Acute Lymphoblastic Leukemia (ALL) · Urinary Bladder Neoplasms · Neoplasm Metastasis

Recently updated registry entries

NCT03486873 — Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who… (Recruiting)
NCT06119581 — A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without… (Recruiting)
NCT07218380 — A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.